A citation-based method for searching scientific literature

Alexander Drilon, Chelsea Jenkins, Sudarshan Iyer, Adam Schoenfeld, Clare Keddy, Monika A Davare. Nat Rev Clin Oncol 2021
Times Cited: 37



Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, D Ross Camidge, Benjamin J Solomon, Ravi Salgia, Gregory J Riely, Marileila Varella-Garcia, Geoffrey I Shapiro, Daniel B Costa, Robert C Doebele, Long Phi Le, Zongli Zheng, Weiwei Tan, Patricia Stephenson, S Martin Shreeve, Lesley M Tye, James G Christensen, Keith D Wilner, Jeffrey W Clark, A John Iafrate. N Engl J Med 2014
Times Cited: 1193




List of shared articles



Times cited

Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer.
Jessica J Lin, Noura J Choudhury, Satoshi Yoda, Viola W Zhu, Ted W Johnson, Ramin Sakhtemani, Ibiayi Dagogo-Jack, Subba R Digumarthy, Charlotte Lee, Andrew Do,[...]. Clin Cancer Res 2021
12


Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant Alterations.
Giorgia Guaitoli, Federica Bertolini, Stefania Bettelli, Samantha Manfredini, Michela Maur, Lucia Trudu, Beatrice Aramini, Valentina Masciale, Giulia Grisendi, Massimo Dominici,[...]. Int J Mol Sci 2021
1

Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers.
Noura J Choudhury, Jaime L Schneider, Tejas Patil, Viola W Zhu, Debra A Goldman, Soo-Ryum Yang, Christina J Falcon, Andrew Do, Yunan Nie, Andrew J Plodkowski,[...]. JTO Clin Res Rep 2021
3

Fusion proteins in lung cancer: addressing diagnostic problems for deciding therapy.
Federica Zito Marino, Greta Alì, Francesco Facchinetti, Luisella Righi, Gabriella Fontanini, Giulio Rossi, Renato Franco. Expert Rev Anticancer Ther 2021
3

Oncogenic driver mutations in non-small cell lung cancer: Past, present and future.
Mathieu Chevallier, Maxime Borgeaud, Alfredo Addeo, Alex Friedlaender. World J Clin Oncol 2021
10


Screening for ROS1 fusions in patients with advanced non-small cell lung carcinomas using the VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody.
Esther Conde, Susana Hernandez, Amparo Benito, Alejandra Caminoa, Pilar Garrido, Fernando Lopez-Rios. Expert Rev Mol Diagn 2021
1

MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer.
Sudarshan R Iyer, Igor Odintsov, Adam J Schoenfeld, Evan Siau, Marissa S Mattar, Elisa de Stanchina, Inna Khodos, Alexander Drilon, Gregory J Riely, Marc Ladanyi,[...]. Mol Cancer Res 2022
0

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date.
Sébastien Gendarme, Olivier Bylicki, Christos Chouaid, Florian Guisier. Curr Oncol 2022
0

Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors.
Clare Keddy, Pushkar Shinde, Kristen Jones, Stefanie Kaech, Romel Somwar, Ujwal Shinde, Monika A Davare. Mol Cancer Ther 2022
0

Lorlatinib Induces Durable Disease Stabilization in a Pancreatic Cancer Patient with a ROS1 p.L1950F Mutation: Case Report.
Janna-Lisa Velthaus, Peter Iglauer, Ronald Simon, Carsten Bokemeyer, Peter Bannas, Niklas Beumer, Charles D Imbusch, Eray Goekkurt, Sonja Loges. Oncol Res Treat 2021
1